Literature DB >> 16984688

Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France.

Valérie Horvais1, Sandrine Touzet, Sabrina François, Stéphanie Bourdy, Gabriel Bellon, Cyrille Colin, Isabelle Durieu.   

Abstract

OBJECTIVES: In France, new guidelines for clinical practices concerning cystic fibrosis came out in 2002, underscoring the need for early and intensive management of this disease. Because no recent health economic studies on cystic fibrosis in France were available, we conducted a cost-analysis study before the new guidelines were put into practice, with a view to a later study on the medical and economic impact of these guidelines.
METHODS: A cost-analysis study was performed of the inpatient and outpatient costs of patients with cystic fibrosis for the 2000-2001 period. The various direct costs were estimated on a sample of sixty-five adult and pediatric patients managed for cystic fibrosis in two reference medical centers. Data were obtained from medical records, and questionnaires were filled out by the patients. Analysis was made from the perspective of the French healthcare system.
RESULTS: We studied sixty-five patients, 54 percent male patients and 72 percent children under 18 years of age. The total cost of cystic fibrosis care totaled 16,189 euros per year and per patient. Outpatient costs accounted for 88 percent of the total cost versus 12 percent for inpatient costs; medication costs were the highest with 21 percent of the total cost for home intravenous antibiotic treatments and 49 percent of the total cost for chronic medications.
CONCLUSIONS: The results show that outpatient costs were higher than inpatient costs, which could be related to the importance granted to home health care in France, notably for intravenous antibiotic treatments given for pulmonary complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984688     DOI: 10.1017/S0266462306051476

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  6 in total

1.  Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe.

Authors:  Karine Chevreul; Morgane Michel; Karen Berg Brigham; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Márta Péntek; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Ulf Persson; Giovani Fattore
Journal:  Eur J Health Econ       Date:  2016-04-08

2.  Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.

Authors:  Mareike Heimeshoff; Helge Hollmeyer; Jonas Schreyögg; Oliver Tiemann; Doris Staab
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.981

3.  [Drug treatment of cystic fibrosis - cost patterns and savings potential for outpatient treatment].

Authors:  Christoph T Baltin; Christina Smaczny; Thomas O Wagner
Journal:  Med Klin (Munich)       Date:  2011-01-16

4.  Staff costs of hospital-based outpatient care of patients with cystic fibrosis.

Authors:  Helge Hollmeyer; Jonas Schreyögg; Ulrich Wahn; Doris Staab
Journal:  Health Econ Rev       Date:  2011-08-03

Review 5.  Home versus hospital intravenous antibiotic therapy for cystic fibrosis.

Authors:  Albert Balaguer; Javier González de Dios
Journal:  Cochrane Database Syst Rev       Date:  2015-12-15

6.  Managing Cystic Fibrosis in Polish Healthcare.

Authors:  Marta Rachel; Stanisław Topolewicz; Andrzej Śliwczyński; Sabina Galiniak
Journal:  Int J Environ Res Public Health       Date:  2020-10-20       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.